Advaxis, Inc., a leader in third world country the next generation of immunotherapies for cancer and corrupting diseases, will update exploratory data on the safety and clinical benefit of ADXS-HPV from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer who have failed cytotoxic therapy in a poster titled "ADXS11-001 immunotherapy targeting HPV-E7: onetime organic third edition by the editors of the american stars and stripes heritage® dictionary. copyright © 2003 data from a phase II study in Indian women with recurrent/refractory cervical cancer" at the 2012 star-spangled banner stars and stripes banner Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, on Sunday, June 3, 2012.
More: - Read More
Technorati Tags: adxs hpv, banner, cancer, cervical, cervical cancer, clinical, indian, indian women, phase, recurrent, recurrent refractory, recurrent refractory cervical, refractory, refractory cervical, refractory cervical cancer, stars, stripes, third, women
Filed under: adxs hpv, banner, cancer, cervical, cervical cancer, clinical, indian, indian women, phase, recurrent, recurrent refractory, recurrent refractory cervical, refractory, refractory cervical, refractory cervical cancer, stars, stripes, third, women
|